Osteoarthritis and Bone Disorders News

Although initially more expensive, a physical therapy course for knee osteoarthritis is more cost-effective after 1 year than a course of glucocorticoid injections, according to data published in JAMA Network Open.

TAMPA, Fla. — External and internal validation of six trained machine learning models showed they performed acceptably in predicting depression in patients with knee osteoarthritis, according to a presenter.

Adding duloxetine to usual care fails to result in any “clinically relevant effect” in patients with chronic hip or knee osteoarthritis pain, compared with usual care alone, according to data published in Arthritis & Rheumatology.

The burden of hip osteoarthritis has increased globally in the past 30 years, with incidence and disability-adjusted life years rising “in nearly all countries,” according to data published in Arthritis Research & Therapy.

Just 0.7% of fully vaccinated patients with inflammatory rheumatic and musculoskeletal disease experience a breakthrough COVID-19 infection, while only 4.4% demonstrate disease flare reactions, according to data.

As many as 9% of Medicare beneficiaries with knee osteoarthritis use opioids chronically, while 21% are occasional users, according to data published in Arthritis Care & Research.

Health care costs remained high for Medicare beneficiaries with common chronic conditions for which brand-name medications without generic alternatives were recommended, according to findings published in JAMA Internal Medicine.

Few randomized clinical trials support using repository corticotropin injection for most FDA-approved indications, including rheumatoid arthritis, ankylosing spondylitis, lupus, optic neuritis and nephrotic syndrome, according to researchers.

Physical activity, defined as recreational whole-body physiological energy expenditure, and time spent in physical activity are not associated with knee osteoarthritis outcomes, according to data published in Arthritis & Rheumatology.

Platelet-rich plasma injections failed to improve knee osteoarthritis symptoms or joint structure at 12 months, compared with a saline placebo, in patients with symptomatic, mild-to-moderate radiographic disease, according to data.